Association of β-blocker use with mortality among patients with congestive heart failure in the Cardiovascular Health Study (CHS)

Jeannie D. Chan, Thomas D. Rea, Nicholas L. Smith, David Siscovick, Susan R. Heckbert, Thomas Lumley, Paulo Chaves, Curt D. Furberg, Lewis Kuller, Bruce M. Psaty

Research output: Contribution to journalArticle

Abstract

Background: In clinical trials, β-blocker therapy reduces all-cause mortality among people with congestive heart failure (CHF) characterized by depressed systolic function, but few trials included large numbers of elderly participants. This study assessed the association between β-blocker therapy and mortality among community-dwelling older adults with CHF. Methods: The Cardiovascular Health Study (CHS) is a longitudinal, population-based study of adults aged ≥65 years. Recruitment began in 1989 with follow-up extending through June 2000 or death. Cox proportional hazard regression models were used to assess the association between β-blocker therapy and all-cause mortality among 950 participants who developed new-onset CHF. Results: β-Blocker users (n = 157) were more likely than nonusers (n = 793) to have treated hypertension, clinical coronary artery disease, and valvular disease at the time of CHF diagnosis. Death occurred in 67 users and 446 nonusers during a median follow-up of 2.3 years. Compared with nonuse, use of β-blockers was associated with a multivariable adjusted hazard ratio (HR) of 0.74 (95% CI 0.56-0.98) for all-cause mortality. Among the 520 participants who had left ventricular ejection fraction assessed within 90 days after CHF diagnosis, the risk for all cause mortality associated with β-blocker use did not differ significantly between those with ejection fraction of

Original languageEnglish (US)
Pages (from-to)464-470
Number of pages7
JournalAmerican Heart Journal
Volume150
Issue number3
DOIs
StatePublished - Sep 2005

Fingerprint

Heart Failure
Mortality
Health
Independent Living
Proportional Hazards Models
Stroke Volume
Coronary Artery Disease
Therapeutics
Clinical Trials
Hypertension
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Chan, J. D., Rea, T. D., Smith, N. L., Siscovick, D., Heckbert, S. R., Lumley, T., ... Psaty, B. M. (2005). Association of β-blocker use with mortality among patients with congestive heart failure in the Cardiovascular Health Study (CHS). American Heart Journal, 150(3), 464-470. https://doi.org/10.1016/j.ahj.2004.12.022

Association of β-blocker use with mortality among patients with congestive heart failure in the Cardiovascular Health Study (CHS). / Chan, Jeannie D.; Rea, Thomas D.; Smith, Nicholas L.; Siscovick, David; Heckbert, Susan R.; Lumley, Thomas; Chaves, Paulo; Furberg, Curt D.; Kuller, Lewis; Psaty, Bruce M.

In: American Heart Journal, Vol. 150, No. 3, 09.2005, p. 464-470.

Research output: Contribution to journalArticle

Chan, JD, Rea, TD, Smith, NL, Siscovick, D, Heckbert, SR, Lumley, T, Chaves, P, Furberg, CD, Kuller, L & Psaty, BM 2005, 'Association of β-blocker use with mortality among patients with congestive heart failure in the Cardiovascular Health Study (CHS)', American Heart Journal, vol. 150, no. 3, pp. 464-470. https://doi.org/10.1016/j.ahj.2004.12.022
Chan, Jeannie D. ; Rea, Thomas D. ; Smith, Nicholas L. ; Siscovick, David ; Heckbert, Susan R. ; Lumley, Thomas ; Chaves, Paulo ; Furberg, Curt D. ; Kuller, Lewis ; Psaty, Bruce M. / Association of β-blocker use with mortality among patients with congestive heart failure in the Cardiovascular Health Study (CHS). In: American Heart Journal. 2005 ; Vol. 150, No. 3. pp. 464-470.
@article{13715e27f20a4af0ad72cd93dd2ce8c7,
title = "Association of β-blocker use with mortality among patients with congestive heart failure in the Cardiovascular Health Study (CHS)",
abstract = "Background: In clinical trials, β-blocker therapy reduces all-cause mortality among people with congestive heart failure (CHF) characterized by depressed systolic function, but few trials included large numbers of elderly participants. This study assessed the association between β-blocker therapy and mortality among community-dwelling older adults with CHF. Methods: The Cardiovascular Health Study (CHS) is a longitudinal, population-based study of adults aged ≥65 years. Recruitment began in 1989 with follow-up extending through June 2000 or death. Cox proportional hazard regression models were used to assess the association between β-blocker therapy and all-cause mortality among 950 participants who developed new-onset CHF. Results: β-Blocker users (n = 157) were more likely than nonusers (n = 793) to have treated hypertension, clinical coronary artery disease, and valvular disease at the time of CHF diagnosis. Death occurred in 67 users and 446 nonusers during a median follow-up of 2.3 years. Compared with nonuse, use of β-blockers was associated with a multivariable adjusted hazard ratio (HR) of 0.74 (95{\%} CI 0.56-0.98) for all-cause mortality. Among the 520 participants who had left ventricular ejection fraction assessed within 90 days after CHF diagnosis, the risk for all cause mortality associated with β-blocker use did not differ significantly between those with ejection fraction of",
author = "Chan, {Jeannie D.} and Rea, {Thomas D.} and Smith, {Nicholas L.} and David Siscovick and Heckbert, {Susan R.} and Thomas Lumley and Paulo Chaves and Furberg, {Curt D.} and Lewis Kuller and Psaty, {Bruce M.}",
year = "2005",
month = "9",
doi = "10.1016/j.ahj.2004.12.022",
language = "English (US)",
volume = "150",
pages = "464--470",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Association of β-blocker use with mortality among patients with congestive heart failure in the Cardiovascular Health Study (CHS)

AU - Chan, Jeannie D.

AU - Rea, Thomas D.

AU - Smith, Nicholas L.

AU - Siscovick, David

AU - Heckbert, Susan R.

AU - Lumley, Thomas

AU - Chaves, Paulo

AU - Furberg, Curt D.

AU - Kuller, Lewis

AU - Psaty, Bruce M.

PY - 2005/9

Y1 - 2005/9

N2 - Background: In clinical trials, β-blocker therapy reduces all-cause mortality among people with congestive heart failure (CHF) characterized by depressed systolic function, but few trials included large numbers of elderly participants. This study assessed the association between β-blocker therapy and mortality among community-dwelling older adults with CHF. Methods: The Cardiovascular Health Study (CHS) is a longitudinal, population-based study of adults aged ≥65 years. Recruitment began in 1989 with follow-up extending through June 2000 or death. Cox proportional hazard regression models were used to assess the association between β-blocker therapy and all-cause mortality among 950 participants who developed new-onset CHF. Results: β-Blocker users (n = 157) were more likely than nonusers (n = 793) to have treated hypertension, clinical coronary artery disease, and valvular disease at the time of CHF diagnosis. Death occurred in 67 users and 446 nonusers during a median follow-up of 2.3 years. Compared with nonuse, use of β-blockers was associated with a multivariable adjusted hazard ratio (HR) of 0.74 (95% CI 0.56-0.98) for all-cause mortality. Among the 520 participants who had left ventricular ejection fraction assessed within 90 days after CHF diagnosis, the risk for all cause mortality associated with β-blocker use did not differ significantly between those with ejection fraction of

AB - Background: In clinical trials, β-blocker therapy reduces all-cause mortality among people with congestive heart failure (CHF) characterized by depressed systolic function, but few trials included large numbers of elderly participants. This study assessed the association between β-blocker therapy and mortality among community-dwelling older adults with CHF. Methods: The Cardiovascular Health Study (CHS) is a longitudinal, population-based study of adults aged ≥65 years. Recruitment began in 1989 with follow-up extending through June 2000 or death. Cox proportional hazard regression models were used to assess the association between β-blocker therapy and all-cause mortality among 950 participants who developed new-onset CHF. Results: β-Blocker users (n = 157) were more likely than nonusers (n = 793) to have treated hypertension, clinical coronary artery disease, and valvular disease at the time of CHF diagnosis. Death occurred in 67 users and 446 nonusers during a median follow-up of 2.3 years. Compared with nonuse, use of β-blockers was associated with a multivariable adjusted hazard ratio (HR) of 0.74 (95% CI 0.56-0.98) for all-cause mortality. Among the 520 participants who had left ventricular ejection fraction assessed within 90 days after CHF diagnosis, the risk for all cause mortality associated with β-blocker use did not differ significantly between those with ejection fraction of

UR - http://www.scopus.com/inward/record.url?scp=24944441753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24944441753&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2004.12.022

DO - 10.1016/j.ahj.2004.12.022

M3 - Article

VL - 150

SP - 464

EP - 470

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 3

ER -